Quest Diagnostics's most recent trend suggests a bearish bias. One trading opportunity on Quest Diagnostics is a Bear Call Spread using a strike $55.00 short call and a strike $65.00 long call offers a potential 8.7% return on risk over the next 25 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $55.00 by expiration. The full premium credit of $0.80 would be kept by the premium seller. The risk of $9.20 would be incurred if the stock rose above the $65.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Quest Diagnostics is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Quest Diagnostics is bearish.
The RSI indicator is at 73.28 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Quest Diagnostics
9:13 am Quest Diagnostics business, Focus Diagnostics, receives FDA clearance for moderate complexity simplexa HSV 1 & 2 direct molecular test for aiding the diagnosis of encephalitis
Tue, 25 Mar 2014 13:13:00 GMT
Focus Diagnostics Receives FDA Clearance for Moderate Complexity Simplexa® HSV 1 & 2 Direct Molecular Test for Aiding the Diagnosis of Encephalitis
Mon, 24 Mar 2014 19:28:09 GMT
noodls – MADISON, N.J. and CYPRESS, Calif., March 24, 2014 /PRNewswire/ — Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information and services, today announced that its Focus Diagnostics …
Focus Diagnostics Receives FDA Clearance for Moderate Complexity Simplexa® HSV 1 & 2 Direct Molecular Test for Aiding the Diagnosis of Encephalitis
Mon, 24 Mar 2014 13:12:00 GMT
PR Newswire – MADISON, N.J. and CYPRESS, Calif., March 24, 2014 /PRNewswire/ — Quest Diagnostics (DGX), the world's leading provider of diagnostic information and services, today announced that its Focus Diagnostics products business has received expedited FDA 510(k) clearance and CLIA moderate complexity categorization for its new Simplexa HSV 1 & 2 Direct molecular test on the 3M Integrated Cycler. The test, which is now available for purchase in the United States, is the first molecular test to be cleared by the FDA for the qualitative detection and differentiation of herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2) in cerebrospinal fluid (CSF) from patients suspected of HSV central nervous system (CNS) infection, including encephalitis. The Infectious Diseases Society of America (IDSA) recommends herpes simplex PCR testing on all CSF specimens in patients with encephalitis. HSV encephalitis occurs in all ages and during all seasons, with HSV-1 encephalitis more common in adults and HSV-2 encephalitis more common in newborn infants.
1 Great Dividend You Can Buy Right Now
Fri, 21 Mar 2014 16:05:56 GMT
CLFS review potential negative for Quest, LabCorp, says Piper Jaffray
Tue, 18 Mar 2014 11:28:50 GMT
Related Posts
Also on Market Tamer…
Follow Us on Facebook